BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32901879)

  • 1. MicroRNA‑218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2.
    Mu L; Guan B; Tian J; Li X; Long Q; Wang M; Wang W; She J; Li X; Wu D; Du Y
    Oncol Rep; 2020 Nov; 44(5):1961-1970. PubMed ID: 32901879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
    Huang J; Wang X; Wen G; Ren Y
    Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma.
    Chen F; Bai J; Li W; Mei P; Liu H; Li L; Pan Z; Wu Y; Zheng J
    PLoS One; 2013; 8(2):e56241. PubMed ID: 23457532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA‑21 contributes to renal cell carcinoma cell invasiveness and angiogenesis via the PDCD4/c‑Jun (AP‑1) signalling pathway.
    Fan B; Jin Y; Zhang H; Zhao R; Sun M; Sun M; Yuan X; Wang W; Wang X; Chen Z; Liu W; Yu N; Wang Q; Liu T; Li X
    Int J Oncol; 2020 Jan; 56(1):178-192. PubMed ID: 31789394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma.
    Gargalionis AN; Sarlani E; Stofas A; Malakou LS; Adamopoulos C; Bamias A; Boutati E; Constantinides CA; Stravodimos KG; Piperi C; Papavassiliou AG; Korkolopoulou P
    Cancer Lett; 2020 Oct; 489():135-143. PubMed ID: 32561414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non‑coding RNA MALAT1 correlates with cell viability and mobility by targeting miR‑22‑3p in renal cell carcinoma via the PI3K/Akt pathway.
    Li Z; Ma Z; Xu X
    Oncol Rep; 2019 Feb; 41(2):1113-1121. PubMed ID: 30431104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10.
    Su B; Han H; Gong Y; Li X; Ji C; Yao J; Yang J; Hu W; Zhao W; Li J; Zhang G; Zhou L
    Cancer Immunol Immunother; 2021 Jun; 70(6):1619-1634. PubMed ID: 33237349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
    Hao P; Kang B; Li Y; Hao W; Ma F
    Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2).
    Gu DH; Mao JH; Pan XD; Zhu H; Chen X; Zheng B; Shan Y
    Oncotarget; 2017 Apr; 8(16):26334-26343. PubMed ID: 28412750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.
    Cui L; Zhou H; Zhao H; Zhou Y; Xu R; Xu X; Zheng L; Xue Z; Xia W; Zhang B; Ding T; Cao Y; Tian Z; Shi Q; He X
    BMC Cancer; 2012 Nov; 12():546. PubMed ID: 23173671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer.
    Guan B; Wu K; Zeng J; Xu S; Mu L; Gao Y; Wang K; Ma Z; Tian J; Shi Q; Guo P; Wang X; He D; Du Y
    Oncotarget; 2017 Jan; 8(5):8162-8172. PubMed ID: 28030804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
    Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
    Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP Promotes VEGFA Expression and Tumor Angiogenesis Though Gli2 in Human Renal Cell Carcinoma.
    Xu S; Zhang H; Chong Y; Guan B; Guo P
    Arch Med Res; 2019 May; 50(4):225-233. PubMed ID: 31518897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway.
    Jiang H; Shi QQ; Ge LY; Zhuang QF; Xue D; Xu HY; He XZ
    Cancer Med; 2019 Aug; 8(10):4836-4844. PubMed ID: 31274247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway.
    Su Y; Lu J; Chen X; Liang C; Luo P; Qin C; Zhang J
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):573-588. PubMed ID: 30511250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
    Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
    Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway.
    Wang N; Wang R; Tang J; Gao J; Fang Z; Zhang M; Shen X; Lu L; Chen Y
    Contrast Media Mol Imaging; 2022; 2022():5602011. PubMed ID: 36176934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway.
    Hou P; Li H; Yong H; Chen F; Chu S; Zheng J; Bai J
    Angiogenesis; 2019 Nov; 22(4):507-519. PubMed ID: 31254127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.